REPLIGEN CORP Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares
REPLIGEN CORP (RGEN) reported Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares of 0 shares for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares · last filed 2026-05-06
- REPLIGEN CORP incremental common shares attributable to dilutive effect of contingently issuable shares for the quarter ending 2026-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- REPLIGEN CORP incremental common shares attributable to dilutive effect of contingently issuable shares for the quarter ending 2025-03-31 was 56.00K shares.
- REPLIGEN CORP incremental common shares attributable to dilutive effect of contingently issuable shares for fiscal 2023 was 8.00 shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares 3 month | Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares 12 month |
|---|---|---|
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-05-06 | |
| 2025-03-31 | 56.00K shares 10-Q · filed 2026-05-06 | |
| 2023-12-31 | 8.00 shares 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |